Revenue
2018
2019
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M | $524.0M | $37.5M | $7.3M | $11.3M | $13.1M | $25.1M | $10.6M | $6.1M |
| Research & development | $140.7M | $143.8M | $214.9M | $197.6M | $143.5M | $122.4M | $94.7M | $74.8M | $72.2M | $72.5M | $59.1M | $43.8M |
| Operating expenses | — | — | $289.5M | $252.7M | $199.8M | $165.0M | $128.3M | $100.1M | $96.8M | $98.5M | $82.5M | $60.8M |
| Operating income | −$185.3M | −$184.3M | −$282.9M | −$143.2M | $310.6M | −$125.4M | −$121.1M | −$88.2M | −$71.3M | −$71.9M | −$71.2M | −$53.7M |
| EBITDAderived | −$170.6M | −$171.7M | −$271.0M | −$134.6M | $317.9M | −$114.8M | −$114.5M | −$75.8M | −$63.8M | — | — | — |
| Net income | −$199.0M | −$239.6M | −$308.5M | −$126.8M | $329.6M | −$125.0M | −$124.2M | −$83.3M | −$79.3M | −$73.4M | −$82.1M | — |
| Basic EPSper diluted share | -$3.46 | -$4.92 | -$6.47 | -$2.71 | $7.17 | -$2.81 | -$3.11 | -$2,340.00 | -$2,940.00 | -$2.93 | -$3.72 | -$2.91 |
| Diluted EPSper diluted share | -$3.46 | -$4.92 | -$6.47 | -$2.71 | $7.04 | -$2.81 | -$3.11 | -$2,340.00 | -$2,940.00 | -$2.93 | -$3.72 | -$2.91 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | Abi-Saab WalidChief Medical Officer | SellOrdinary Shares | 1.4K | $46.86 | $67.2K | 168.2K |
| Jun 25, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 28.7K | $50.02 | $1.44M | 519.2K |
| Jun 24, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 6.7K | $50.00 | $334.8K | 519.2K |
| Jun 18, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 37.0K | $50.00 | $1.85M | 521.8K |
| Jun 18, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 4.7K | $50.00 | $232.8K | 558.8K |